DK0606248T3 - Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer - Google Patents

Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer

Info

Publication number
DK0606248T3
DK0606248T3 DK92918761T DK92918761T DK0606248T3 DK 0606248 T3 DK0606248 T3 DK 0606248T3 DK 92918761 T DK92918761 T DK 92918761T DK 92918761 T DK92918761 T DK 92918761T DK 0606248 T3 DK0606248 T3 DK 0606248T3
Authority
DK
Denmark
Prior art keywords
heteroberlamines
acetylcholinesterase inhibitors
novel acetylcholinesterase
novel
inhibitors
Prior art date
Application number
DK92918761T
Other languages
Danish (da)
English (en)
Inventor
Yuhpyng L Chen
Arthur A Nagel
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DK0606248T3 publication Critical patent/DK0606248T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK92918761T 1991-10-03 1992-08-31 Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer DK0606248T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77128391A 1991-10-03 1991-10-03
PCT/US1992/007230 WO1993007140A1 (en) 1991-10-03 1992-08-31 Heteroaryl amines as novel acetyl cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
DK0606248T3 true DK0606248T3 (da) 2003-06-23

Family

ID=25091318

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92918761T DK0606248T3 (da) 1991-10-03 1992-08-31 Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer

Country Status (36)

Country Link
US (4) US5574046A (fi)
EP (1) EP0606248B1 (fi)
JP (1) JP2546785B2 (fi)
KR (1) KR0170458B1 (fi)
CN (1) CN1035615C (fi)
AP (1) AP314A (fi)
AT (1) ATE235490T1 (fi)
AU (1) AU667053B2 (fi)
BG (1) BG61727B1 (fi)
BR (1) BR9206577A (fi)
CA (1) CA2119647C (fi)
CZ (1) CZ290807B6 (fi)
DE (2) DE9290112U1 (fi)
DK (1) DK0606248T3 (fi)
EG (1) EG21481A (fi)
ES (1) ES2193137T3 (fi)
FI (1) FI116939B (fi)
HU (1) HU225049B1 (fi)
IL (1) IL103274A (fi)
IS (1) IS1745B (fi)
MA (1) MA22672A1 (fi)
MX (1) MX9205678A (fi)
NO (1) NO308533B1 (fi)
NZ (1) NZ244601A (fi)
OA (1) OA09895A (fi)
PH (1) PH31290A (fi)
PL (3) PL171984B1 (fi)
PT (1) PT100917B (fi)
RO (1) RO112868B1 (fi)
RU (1) RU2100357C1 (fi)
SG (1) SG52618A1 (fi)
TW (1) TW263504B (fi)
UA (1) UA41290C2 (fi)
UY (1) UY23484A1 (fi)
WO (1) WO1993007140A1 (fi)
ZA (1) ZA927589B (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
MXPA03003397A (es) * 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
CA2501547A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
JP2007537294A (ja) * 2004-05-14 2007-12-20 ザ・ジョンズ・ホプキンス・ユニバーシティー Gababレセプターアンタゴニストとアセチルコリンエステラーゼインヒビターとの同時投与により認識機能を改善するための方法
EP1600447A1 (en) * 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
PE20060430A1 (es) 2004-06-09 2006-05-25 Glaxo Group Ltd Derivados de pirrolopiridina como moduladores de los receptores cannabinoides
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
CN1808106B (zh) * 2005-01-21 2010-11-24 中国科学院上海药物研究所 一种用核磁共振筛选乙酰胆碱酯酶抑制剂的方法
EP2324126B1 (en) 2008-08-12 2014-04-23 Zinfandel Pharmaceuticals, Inc. METHOD OF IDENTIFYING Alzheimer's DISEASE RISK FACTORS
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
AU2010302584B2 (en) 2009-10-02 2015-09-10 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
MA34828B1 (fr) 2011-01-10 2014-01-02 Zinfandel Pharmaceuticals Inc Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
KR102268357B1 (ko) 2013-01-29 2021-06-23 아벡신 에이에스 항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN107141266B (zh) * 2017-06-28 2019-04-09 佳木斯大学附属第一医院 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL100127C (fi) * 1954-04-28
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4122265A (en) * 1976-05-21 1978-10-24 Hoffmann-La Roche Inc. Derivatives of 3-phenylisoindole-1-carboxylic acid
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
US5064840A (en) * 1989-08-03 1991-11-12 Merrell Dow Pharmaceuticals Anti-psychotic piperidylbenzimidazole compounds
TW197442B (fi) * 1990-02-08 1993-01-01 Pfizer
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
TW197435B (fi) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
AU669156B2 (en) * 1992-02-13 1996-05-30 Merrell Dow Pharmaceuticals Inc. Piperidinyl thiacyclic derivatives
CA2092112A1 (en) * 1992-03-23 1993-09-24 Nobuyoshi Iwata Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use

Also Published As

Publication number Publication date
US6124321A (en) 2000-09-26
DE69232976T2 (de) 2003-10-02
MA22672A1 (fr) 1993-07-01
KR0170458B1 (ko) 1999-02-18
BG61727B1 (bg) 1998-04-30
IL103274A (en) 1996-11-14
CZ290807B6 (cs) 2002-10-16
PL171984B1 (pl) 1997-07-31
FI941518A (fi) 1994-03-31
HU225049B1 (en) 2006-05-29
EP0606248B1 (en) 2003-03-26
NZ244601A (en) 1995-03-28
PH31290A (en) 1998-07-06
AU2519692A (en) 1993-05-03
CA2119647C (en) 1998-08-04
PL171669B1 (en) 1997-06-30
DE9290112U1 (de) 1994-06-01
US6303633B1 (en) 2001-10-16
FI116939B (fi) 2006-04-13
MX9205678A (es) 1993-04-01
BR9206577A (pt) 1995-10-10
FI941518A0 (fi) 1994-03-31
BG98689A (bg) 1995-03-31
AP9200421A0 (en) 1992-10-31
ATE235490T1 (de) 2003-04-15
DE69232976D1 (de) 2003-04-30
RO112868B1 (ro) 1998-01-30
EG21481A (en) 2001-11-28
CN1071166A (zh) 1993-04-21
JP2546785B2 (ja) 1996-10-23
UY23484A1 (es) 1993-03-11
UA41290C2 (uk) 2001-09-17
CA2119647A1 (en) 1993-04-15
IS1745B (is) 2000-05-18
JPH06510788A (ja) 1994-12-01
OA09895A (en) 1995-09-15
US20020049210A1 (en) 2002-04-25
IL103274A0 (en) 1993-02-21
PL171693B1 (pl) 1997-06-30
NO941179D0 (no) 1994-03-30
NO308533B1 (no) 2000-09-25
CN1035615C (zh) 1997-08-13
TW263504B (fi) 1995-11-21
ES2193137T3 (es) 2003-11-01
EP0606248A1 (en) 1994-07-20
IS3919A (is) 1993-04-04
AP314A (en) 1994-02-04
US5574046A (en) 1996-11-12
HU9400952D0 (en) 1994-06-28
CZ78594A3 (en) 1995-07-12
HUT70544A (en) 1995-10-30
PT100917B (pt) 1999-07-30
WO1993007140A1 (en) 1993-04-15
RU2100357C1 (ru) 1997-12-27
ZA927589B (en) 1994-04-05
PT100917A (pt) 1993-11-30
AU667053B2 (en) 1996-03-07
NO941179L (no) 1994-03-30
SG52618A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
DK0606248T3 (da) Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer
FI933167A (fi) N-alkylkinuklidiniumsalter som substans-p antagonister
FI934568A0 (fi) Hydrofobisitet som aostadkommits med metalljonaktivering
FI944804A (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
FI931229A0 (fi) Som glanspigment laempade blandningar
FI921182A (fi) Velangummi som snabbt hydratiseras
NO940305D0 (no) Kinazolin-derivater som acetylcholin-esteraseinhibitorer
FI931111A0 (fi) Staongtvaolskompositioner som innehaoller sackaros
FI931069A0 (fi) Kolloidalt rostat kaffe som aromatiseringsprodukt
FI922973A (fi) Tokoferolblandning foer anvaendning som antioxidant foer krusmyntolja i tuggummi
DK0409676T3 (da) Acetylcholinesterase-inhibitorer
NO922167L (no) Aminodukter som korrosjonshemmere
FI930722A0 (fi) Foerfarande foer framstaellning av polymerer som innehaoller ammoniumgrupper
FI934764A (fi) Anordning som hindrar krympning av kabelisolering
FI923555A (fi) Foerfarande foer framstaellning av mattor som bestaor av minst tvao med varandra bundna skikt
FI921666A (fi) Indolin- och dihydrokinolinfoereningar som oeppnare av kaliumkanal
FI930342A0 (fi) Pentapeptider som reglerar immun- och nervsystem
FI924440A (fi) Heterocykliska foereningar som aldosreduktasinhibitorer
FI930219A (fi) Anvaendning av reaktionsblandningar som gjutbara massor
FI935826A0 (fi) Kallsmoerjmedel med delvis neutraliserade fosforsyraestrar som EP-tillsatsaemnen
NO912574D0 (no) Piperidinylforbindelser og deres anvendelse som tilsetningsmidler.
FI931092A0 (fi) Vapen som innefattar en styrlina
FI914768A (fi) Foer stoedmurar laempad staolprofil med kantig sammanfogning som arbetsoeppning
FI930618A0 (fi) Proteaser som foerorsakar onormal nedbrytning av amyloid-b-protein
FI922997A (fi) Tuggummi som innehaoller verksamma aemnen